Quantcast

Latest Organofluorides Stories

2014-07-13 23:03:21

As Lipitor Lawsuits Await Litigation The First Bellwether Trial Has Been Scheduled For July of 2015 With Depositions to Start This August Reports Wright & Schulte LLC Columbus, OH (PRWEB) July 13, 2014 Wright & Schulte LLC has learned that the first Lipitor bellwether trial has been scheduled in July of 2015, in U.S. District Court, District of South Carolina. The Lipitor lawsuits are in the discovery process in the South Carolina federal court where District Judge Richard M....

2014-07-10 23:03:47

Fluorocarbon Refrigerants can be segmented by Geographies, Companies, Applications and Ingredients. http://www.micromarketmonitor.com/market-report/fluorocarbon-refrigerants-reports-6093777763.html. (PRWEB) July 10, 2014 Fluorocarbons are the most commonly used refrigerants. Chlorofluorocarbons (CFC), Hydrochlorofluorocarbons (HCFC), and Hydrofluorocarbons (HFC) are the types of fluorochemicals commonly used as refrigerants. However, due to the relatively high ODPs and GWPs, CFC and HCFC...

2014-07-10 08:27:07

LUGANO, Switzerland, July 10, 2014 /PRNewswire/ -- Helsinn Group, the company focused on building quality cancer care, today announces that the complete results of the three Phase 2/3 pivotal trials for the investigational oral fixed-dose combination capsule of netupitant 300 mg + oral palonosetron 0.50 mg (NEPA), which is licensed to Eisai Inc. in the United States, have been published, together with an accompanying editorial, in the July issue of Annals of Oncology....

2014-07-09 08:27:55

WOODCLIFF LAKE, N.J., July 9, 2014 /PRNewswire/ -- Par Pharmaceutical Companies, Inc. today announced that it has received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for fluphenazine decanoate injection, USP 25 mg/mL. Fluphenazine decanoate injection is a long-acting parenteral antipsychotic drug intended for use in the management of patients requiring prolonged parenteral neuroleptic therapy (e.g., chronic schizophrenics)....

2014-07-07 23:00:59

Launch of the Risperdal Lawsuits for Gynecomastia Page Comes as Hundreds of Plaintiffs Seek Compensation for Gynecomastia, a Condition Marked by the Excessive Growth of Male Breast Tissue, Which is Allegedly Caused by Risperdal. Chicago IL (PRWEB) July 07, 2014 The Oliver Law Group P.C. a harmful drug law firm, announces that they have launched a Risperdal lawsuit for Gynecomastia page in response to the growing Risperdal gynecomastia litigation underway in Pennsylvania state court. Court...

2014-07-07 08:22:14

-- Nexavar is the only approved treatment for patients with RAI-refractory differentiated thyroid cancer -- Nexavar significantly extended progression-free survival in patients with RAI-refractory differentiated thyroid cancer compared to placebo in the Phase III DECISION trial TORONTO, July 7, 2014 /CNW/ - Bayer Inc. is pleased to announce the Health Canada approval of Nexavar for the treatment of patients with locally...

2014-07-03 23:01:07

The Firm is representing a number of Risperdal lawsuit clients in the Pennsylvania litigation who allegedly developed gynecomastia (male breast growth) due to their use of the atypical antipsychotic drug. New York, New York (PRWEB) July 03, 2014 Risperdal lawsuits (http://www.risperdallawsuitcenter.com/) that allege the atypical antipsychotic medication caused gynecomastia (male breast growth) in men and boys continue to move forward in a mass tort proceeding underway in Pennsylvania’s...

2014-07-03 20:20:02

Tokyo, July 3, 2014 - (JCN Newswire) - Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that it has received approval from the European Commission of the indication expansion of Halaven (generic name: eribulin mesylate, "eribulin") to contribute to earlier treatment of patients with locally advanced or metastatic breast cancer who have progressed after at least one chemotherapeutic regimen for advanced disease. Prior therapy should...

2014-07-02 12:13:46

The JAMA Network Journals Despite strong preclinical data, the drug everolimus failed to improve overall survival in patients with advanced liver cancer, compared to placebo, according to a study in the July 2 issue of JAMA. Patients with advanced hepatocellular carcinoma (HCC; a type of liver cancer) have a median overall survival of less than l year, largely because of the absence of effective therapies. The drug sorafenib is the only systemic therapy shown to significantly improve...

2014-07-02 08:24:16

LONDON, July 2, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report: AstraZeneca PLC - Product Pipeline Review - 2014 http://www.reportbuyer.com/computing_electronics/manufacturing/astrazeneca_plc_product_pipeline_review_2013.html AstraZeneca PLC - Product Pipeline Review - 2014 Summary Global Markets Direct's, 'AstraZeneca PLC - Product Pipeline Review - 2014', provides an overview of the AstraZeneca PLC's pharmaceutical research and development focus....


Word of the Day
jument
  • A beast of burden; also, a beast in general.
'Jument' ultimately comes from the Latin 'jugum,' yoke.
Related